<DOC>
	<DOCNO>NCT02902965</DOCNO>
	<brief_summary>This Phase 2 open-label study evaluate efficacy safety ibrutinib combination bortezomib dexamethasone patient relapse relapsed refractory multiple myeloma .</brief_summary>
	<brief_title>Study Ibrutinib Combination With Bortezomib Dexamethasone Subjects With Relapsed/Relapsed Refractory Multiple Myeloma</brief_title>
	<detailed_description>Bruton 's tyrosine kinase ( Btk ) enzyme present hematopoeitic cell T cell necessary downstream signal transduction various hematopoietic receptor include B cell receptor well Fc , chemokine adhesion receptor , crucial B cell development osteoclastogenesis . Although down-regulated normal plasma cell , Btk highly express malignant cell many myeloma patient cell line . Ibrutinib potent specific inhibitor Btk currently Phase 2 3 clinical trial . The current study design intend determine safety efficacy ibrutinib combination bortezomib dexamethasone subject relapsed/relapsed refractory multiple myeloma .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Subjects multiple myeloma ( MM ) receive 13 prior line therapy demonstrate disease progression since completion recent treatment regimen . ( Subjects may receive prior bortezomib exposure meet exclusion criterion prior proteasome inhibitor use ) Measurable disease define least one following : Serum monoclonal protein ( SPEP ) ≥1 g/dL ( subject immunoglobulin A ( IgA ) , immunoglobulin D ( IgD ) , immunoglobulin E ( IgE ) immunoglobulin M ( IgM ) multiple myeloma SPEP ≥0.5 g/dL ) Urine monoclonal protein ( UPEP ) ≥200 mg 24 hour urine electrophoresis Adequate hematologic , hepatic renal function Eastern Cooperative Oncology Group ( ECOG ) performance status ≤2 Subject must primary refractory disease Refractory nonresponsive prior proteasome inhibitor ( PI ) therapy ( bortezomib carfilzomib ) Peripheral neuropathy Grade ≥2 Grade 1 pain Screening Plasma cell leukemia , primary amyloidosis , POEMS syndrome Unable swallow capsule disease significantly affect gastrointestinal function Requires treatment strong CYP3A inhibitor Women pregnant breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Bruton 's Tyrosine Kinase</keyword>
	<keyword>Bortezomib</keyword>
	<keyword>Dexamethasone</keyword>
	<keyword>Ibrutinib</keyword>
</DOC>